NLRP3 and hepatocellular carcinoma: ZDHHC12 promotes ovarian cancer progression and cisplatin resistance.[36] In addition, ZDHHC12 is thought to promote glioma progression.[37] The palmitoylation of NLRP3 by ZDHHC12 inhibits the inflammatory response, and although there are no relevant studies in cancers, this finding suggest that ZDHHC12 inhibits cancer progression.[17, 38] The role of ZDHHC12 in HCC remains underexplored.